Trial reportTheranostics2017
Clinical efficacy of omalizumab in chronic spontaneous urticaria is associated with a reduction of FcεRI-positive cells in the skin.
Trial report in Theranostics, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 56 papers, 4 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
56 citing papers in PubMed, 4 syntheses or guidelines pooled it, 134 citations in OpenAlex.
- Efficacy and safety of Omalizumab in the treatment of CSU: a meta-analysis of a randomized controlled trial.Archives of dermatological research · 2025Pooled it
- Cost-effective omalizumab dosage for chronic urticaria: a systematic review and network meta-analysis.Archives of dermatological research · 2024Pooled it
- Time-course and dose-effect of omalizumab in treating chronic idiopathic urticaria/chronic spontaneous urticaria.European journal of clinical pharmacology · 2024Pooled it
- Comparative efficacy and safety of the treatment by Omalizumab for chronic idiopathic urticaria in the general population: A systematic review and network meta-analysis.Skin research and technology : official journal of International Society for Bioengineering and the Skin (ISBS) [and] International Society for Digital Imaging of Skin (ISDIS) [and] International Society for Skin Imaging (ISSI) · 2024Pooled it
- Response of FcεRI-bearing leucocytes to omalizumab in chronic spontaneous urticaria.Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology · 2020Trial
- Trial
- Targeting immune dysregulation in chronic spontaneous urticaria: beyond antihistamines.The Korean journal of internal medicine · 2026Review
- CURE: a phase-based therapeutic framework for chronic inflammation.Frontiers in immunology · 2026Review
- Omalizumab in Refractory Adult-Onset Facial Atopic Dermatitis: A Case Report.Clinical, cosmetic and investigational dermatology · 2026Article
- Efficacy and safety of CT-P39, an omalizumab biosimilar, in chronic spontaneous urticaria: 16-week follow-up study.Clinical and translational allergy · 2025Article
- Spectrum and Impact of Reported Side Effects of Omalizumab in Patients With Chronic Urticaria: A Long-Term Multicentre Real-World Study.Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology · 2025Article
- Biological and target synthetic treatments for chronic spontaneous urticaria: A systematic review and network meta-analysis.Clinical and translational allergy · 2025Article
- Article
- Predictors of response to omalizumab and relapse in chronic spontaneous Urticaria: a narrative review focusing on parameters available in routine clinical practice.Frontiers in allergy · 2025Review
- Predictors of early treatment response to antihistamines and omalizumab in chronic spontaneous urticaria.Frontiers in allergy · 2025Review
- Therapies for Chronic Spontaneous Urticaria: Present and Future Developments.Pharmaceuticals (Basel, Switzerland) · 2024Review
- Sustained clinical and histopathological remission in a patient with eosinophilic esophagitis and type-2 comorbidities at 18 months after discontinuation of dupilumab.Clinical journal of gastroenterology · 2024Article
- Research hotspots in urticaria: A bibliometric study of the top 100 most cited articles.Skin research and technology : official journal of International Society for Bioengineering and the Skin (ISBS) [and] International Society for Digital Imaging of Skin (ISDIS) [and] International Society for Skin Imaging (ISSI) · 2024Article
- Different doses and courses of omalizumab for patients with chronic spontaneous urticaria: A systematic review with meta-analysis and trial sequential analysis.The World Allergy Organization journal · 2024Article
- Early Assessment of Efficacy and Safety of Biologics in Pediatric Allergic Diseases: Preliminary Results from a Prospective Real-World Study.Children (Basel, Switzerland) · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors at 5 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.